| VEENAT 100mg : |
Each capsule contains Imatinib Mesylate equivalent to Imatinib 100mg. |
|
| matinib Mesylate is a protein - tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia Chromosome abnormality in Chronic Myeloid Leukemia (CML). |
|
| |
| Indications: |
| VEENAT (Imatinib Mesylate) is indicated for the treatment of patients with Philadelphia Chromosome positive Chronic Myeloid Leukemia (CML) in blast crisis, accelerated phase, or in chronic phase. |
|
| |
| Dosage & Usage: |
Therapy should be initiated under experienced medical guidance in the treatment of patient with Chronic Myeloid Leukemia (CML).
The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400mg under chronic phase & 600mg under accelerated phase should be administered once daily or as prescribed by your doctor. |
|
| |
| Side Effects: |
| Some common side effects that may occur as a result of the usage of Veenat, include - nausea, vomiting, diarrhea, muscle cramps. If these symptoms persist or worsen, contact your doctor immediately. |
|
| |
| Note: |
| Veenat is a prescription drug and should be used under proper medical guidance and advice. |
|
